Abstract
As antiretroviral treatment (ART) for HIV/AIDS is scaled up globally, information on per-person costs is critical to improve efficiency in service delivery and to maximize coverage and health impact. The objective of this study was to review studies on unit costs for delivery of adult and paediatric ART per patient-year, and prevention of mother-to-child transmission (PMTCT) interventions per mother-infant pair screened or treated, in lowand middle-income countries. A systematic review was conducted of English, French and Spanish publications from 2001 to 2009, reporting empirical costing that accounted for at least antiretroviral (ARV) medicines, laboratory testing and personnel. Expenditures were analysed by country-income level and cost component. All costs were standardized to $US, year 2009 values. Several sensitivity analyses were conducted.
Analyses covered 29 eligible, comprehensive, costing studies. In the base case, in low-income countries (LIC), median ART cost per patient-year was $US792 (mean: 839, range: 682-1089); for lower-middle-income countries (LMIC), the median was $US932 (mean: 1246, range: 156-3904); and, for upper-middle-income countries (UMIC), the median was $US1454 (mean: 2783, range: 1230-5667). ARV drugs were the largest component of overall ART costs in all settings (64%, 50% and 47% in LIC, LMIC and UMIC, respectively). Of 26 ART studies, 14 reported the drug regimes used, and only one study explicitly reported second-line treatment costs. The second cost driver was laboratory cost in LIC and LMIC (14% and 20%), and personnel costs in UMIC (26%). Two ART studies specified the types of laboratory tests costed, and three studies specifically included above facility-level personnel costs. Three studies reported detailed PMTCT costs, and three studies reported on paediatric ART.
There is a paucity of data on the full unit costs for delivery of ART and PMTCT, particularly for LIC and middle-income countries. Heterogeneity in activities costed, and insufficient detail regarding components included in the costing, hampers standardization of unit cost measures. Evaluation of programme-level unit costs would benefit from international guidance on standardized costing methods, and expenditure categories and definitions. Future work should help elucidate the sources of the large variations in delivery unit costs across settings with similar income and epidemiological characteristics.
As antiretroviral treatment (ART) for HIV/ AIDS is scaled up globally, information on perperson costs is critical to improve efficiency in service delivery and to maximize coverage and health impact. Cost evaluations support programme planning and budgeting, can help to ensure programme sustainability, and are a pre-requisite to identifying opportunities for efficiency gains. [1, 2] As global health institutions strive to ensure 'value for money', they are committed to supporting countries in the measurement of per-person delivery costs of key services. [3] [4] [5] [6] [7] [8] Since 2008, many national HIV/AIDS programmes have made important advances in complying with the bi-annual routine reporting of nationally aggregated expenditures as stated in the 2001 Declaration of Commitment on HIV/AIDS (UNGASS) to UNAIDS (the Joint United Nations Programme on HIV/ AIDS). [9] UNAIDS summaries of UNGASS data try to standardize reported programme expenditures for ART and PMTCT as per-person costs, [10] but do not request a comprehensive breakdown of the cost components included in each service area. As of 2011, most HIV/AIDS programmes do not routinely assess their cost per person or per unit of service delivery, nor do they breakdown expenditure by cost components using standardized methods.
For antiretroviral treatment (ART), scale-up of treatment access in low-and middle-income studies started in 2004-5, when funding increased substantially with new donor funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the US President's Emergency Plan for AIDS Relief (PEPFAR), among others. As at the end of 2009, an estimated 5.2 million HIVinfected people were receiving ART globally. With the WHO's revised 2010 guidelines on HIV treatment in resource-limited settings, the total immediate need is now estimated at 15 million eligible people worldwide. [11] The ongoing scaleup and progress toward universal access will depend on both total available funding and the delivery cost per patient-year in countries with high HIV prevalence. Previous reviews of facility-level or per-patient ART costs found only a very small number of studies from low-and middle-income countries [12, 13] and estimated the cost of antiretroviral (ARV) medicines from manufacturers' procurement price lists, as an average per country-income group. [13] For prevention of mother-to-child transmission (PMTCT) of HIV, (unit) delivery costs have not been reviewed since 2000. [14] The most recent review of ART costs [15] included more studies from lowand middle-income countries and presented a scoring system to rate the methodological quality of studies -without attempting a quantitative metaanalysis of cost results.
To complement these reviews, we conducted a systematic literature review and a quantitative analysis of per-patient expenditure for adult and paediatric ART, as well as ARV prophylaxis used for PMTCT, using explicit guidelines [16] for systematic reviews, and standardizing data from eligible studies into common service delivery units and cost component categories. Per-patient costs are presented as median, arithmetic average and ranges across eligible study sites, studies, countries and country-income groupings, separately for the most important standardized cost components. We discuss results in the light of information requirements anticipated from national AIDS programmes from major global financiers of HIV/ AIDS programme scale-up.
Literature Review

Search
The literature search followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (figure 1). [16] References identified as relevant served to track additional studies of interest. Annex A details the search terms used on electronic databases; annex B shows the search commands and number of studies found (all annexes are available as Supplemental Digital Content only; http://links.adis online.com/PCZ/A117).
Inclusion Criteria
The following inclusion criteria were applied. A list of excluded studies is available in Annex D.
Country-specific, empirical measurement of actual expenditure, from a micro-costing or ingredients approach (if the study used solely a step-down approach, it was excluded). Study (or study data point) included at least 25 patients. Low-and middle-income countries, according to the July 2009 World Bank list of economies, [17] with both publication and data collection between January 2001 and October 2009.
Costing included at least ARVs, laboratory expenses and personnel, as three individually reported expenditure components, or as explicitly named components of a comprehensive but unbundled overall expenditure. Economic costs from the healthcare provider perspective; financial costs included if economic costs were not available. Economic costs accruing to patients, such as waiting and/or transportation time and productivity losses were not considered because of the inherent difficulties associated with assigning opportunity costs in the absence of accurate data on wages and time costs.
Data Extraction
Eligible articles were reviewed for inclusion by at least two independent reviewers (OG and VW or AML), using a pre-determined data extraction form (see Annex C). When the decision was 'in doubt', a third or fourth reviewer (YST or AFL) analysed the article and inclusion was solved by consensus. If the information contained in the full-text article was incomplete, the authors were contacted to obtain missing data.
Standardization of Data
ART delivery unit cost data were standardized as estimates per patient-year, separately for firstand second-line ART, or weighed by the local mix of patients. Paediatric ART was distinguished from adult ART, using an age cut-off of 15 years. Components of total costs were categorized as follows.
ARVs, including, if available, transport of drugs to point of care, and storage. Personnel involved in delivering ART, including education and training, as well as suprafacility-level human resources, if specified (such as personnel in distribution centres or district/ provincial/national programme management, or monitoring and evaluation [18] (except for a study of ART in Lesotho, [19] for which rates were directly from a Central Bank [20] source, for lack of the relevant exchange rate from the IMF). Once converted into $US, costs were adjusted for inflation using the US Consumer Price Index.
[21]
Data Aggregation and Sensitivity Analysis
The analysis focused on economic costs from the perspective of the provider. Specified economic costs to the patient were included only if a monetary transaction took place so that the service would occur (e.g. a co-payment or recuperation fee paid by the patient), in which case they were added to the overall costs.
Unit costs and unit cost components were summarized as mean, median and range across countries studied (after aggregation across multiple sites, or data points within each country) and country-income groups: low-income countries (LIC), lower-middle-income countries (LMIC) and upper-middle-income countries (UMIC), according to the World Bank 2009 country classification. [17] This method of aggregation prevented countries with relatively large numbers of data points from skewing the results. In sensitivity analyses, we explored the robustness of results against alternative ways of aggregating results across sites, countries and country-income groupings, and robustness of different study inclusion criteria.
Results
Of 574 abstracts retrieved, 150 full-text studies were assessed for eligibility; of those, 29 were included in the analysis: 26 on ART (23 on adult ART, 2 on adult and paediatric ART [22, 23] and 1 on paediatric ART only) [24] (table I) . Table II 
Antiretroviral Treatment
Six studies from four LIC were included (Benin, Ethiopia, Haiti and Uganda); the median cost per patient-year of ART was $US792 (mean: 839, range: 682-1089) [table II] . [23, [25] [26] [27] [28] [29] Studies for LMIC were found for India, [30, 31] Lesotho, [19] Morocco, [32] Nigeria [33, 34] and Thailand; [35] the median cost of ART was $US932 (mean: 1246, range: 156-3904) [table II]. In UMIC -Brazil, [24, 36] Mexico [37] [38] [39] and South Africa [22, [40] [41] [42] [43] [44] [45] [46] -the median ART cost was $US1454 (mean: 2783, range:
ART unit costs and their components varied considerably between both countries and studies b Refers to the ARV line costed by the study.
c Refers to the number of facilities in which the costs were collected; whether the programme was national or local; and whether the provider was different from public/local government (i.e. NGO, FBO or D).
d International dollars converted into $US using the purchase power parity conversion factor provided by the UN Statistical Office. [47] e The study reports the average costs.
f Outpts only (includes patients aged ‡15 years).
g The costs collected are financial costs.
h The study reports the median costs.
i Includes children (<15 years).
j Costs calculated using patients retained 'at the end of the study' as denominator.
k The study includes programmatic cost.
l Costs taken were for 'first-line, annually thereafter' (i.e. first-line patients only, from their 6th month after ART initiation onwards).
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(such as South Africa [22, [40] [41] [42] [43] [44] [45] [46] ) and between sites within one study (e.g. Gupta et al., [30] ) [ figure 2] . While variations between studies may in part reflect differences in costing methods and definitions, variations within studies point to the existence of real differences in actual cost between sites and/or patient populations.
Antiretroviral Medicines
In all three income groups, ARV medicines were the largest cost component. In LIC, they represented 64% of the overall costs, at a median $US428 per patient-year n Average between first and second year of follow-up.
o Public sector only, with patients paying a fixed portion of ART (included in the costs listed).
p The study reports the average cost. Because the investigation reports the cost per visit, cost were multiplied times the average number of visits per year to have an annual parameter.
Because the hospital charges an extra 15%, we multiplied by 85% to obtain the actual cost of the ART delivery. t Costs concern ART given for tx occurring 6-12 months for first-line ART (pt specific) and separately for second-line tx.
u Average between first and second year of tx.
v Because the study reports the costs per month those costs were multiplied by 12 to have an annual parameter.
w Includes patients aged ‡15 years. 3TC = lamivudine; ARV = antiretroviral; AZT = zidovudine; d4T = stavudine; D = donor; DDL = didanosine; EFV = efavirenz; FBC = full blood count; FBO = faith-based organization; IDV = indinavir; inpts = inpatients; INU = included but not unbundled; LPV = lopinavir; NA = not available; Nat = national (if Nat not mentioned it means that the provider is local); NFV = nelfinavir; NGO = non-government organization; NVP = nevirapine; outpts = outpatients; PEPFAR = The President's Emergency Plan for AIDS Relief; R = rural; RTV = ritonavir; tx = treatment(s); U = urban. Twelve studies specifically reported costs for first-line treatment; one study [40] specifically included second-line treatment but those specific costs were excluded. See table I, text and Supplemental Digital Content, 1 (http://links.adisonline.com/PCZ/A117) for further details.
b The total number of countries in scenario 3 adds to 12 only because, given the timing of the costing, and the country's economic development, South Africa is in both the lower-middle-income and the upper-middle-income categories. Fig. 2 . Unit costs for delivery of antiretroviral treatment (ART), per patient-year, by cost component, country and site. [19, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [33] [34] [35] [36] [37] [38] [40] [41] [42] [43] [44] [45] [46] Countries are ranked from left to right according to increasing per capita gross national income (GNI) and then by year of study publication. Studies including (or limited to) paediatric ART are indicated with an asterisk ( * ) over the bar. 'Other costs' refer to components of ART other than antiretroviral (ARV) medicines, laboratory and personnel costs; 'other costs' are not comparable across studies because they do not contain the same elements. Unbundled costs refer to the overall cost of ART in case the study did not report the separate cost components -but these still included at least the three main components under review. Each bar represents a separate data point within each country or study (e.g. different region, health facility/site, patient type, delivery modality, temporality, etc.). GNI per capita (year 2009 values): Ethiopia $US280, Uganda $US420, Haiti $US660, Benin $US690, India $US1070, Lesotho $US1080, Nigeria $US1160, Thailand $US2840, South Africa $US5820, Brazil $US7350, Mexico $US9980. See table I for additional details. PEPFAR = US President's Emergency Plan for AIDS Relief; PHR = The Partners for Health Reformplus. b Refers to the city and the type of location.
c Refers to the year for which the study reported the costs.
d Refers to the number of facilities in which the costs were collected.
e Refers to the number of patients studied to cost the ART delivery.
f Refers to the type of ART provider.
g ARV line costed by the study.
h The mother was given one tablet of NVP 200 mg at the onset of labour and the neonate was given NVP 2 mg/kg bodyweight within 72 hours of birth.
i This cost includes re-issue of NVP to mothers, and provision of NVP suspension to the child and any formula milk for the duration of the hospital stay.
j PMTCT activities delivered after the mother and infant are discharged from hospital after delivery, including CTX and the provision of formula feeding. It does not include infant HIV testing.
ARV = antiretroviral; CTX = cotrimoxazole; D = donor; FBO = faith-based organization; INU = included but not unbundled; NA = not available in the study; Nat = National (if Nat not mentioned it means that the provider is local); NGO = non-government organization; NVP = nevirapine; R = rural; U = urban.
ported details of the types of personnel included. [27, 31, 36, 40, 42, 44, 45] Of these, three included above-facility-level personnel such as human resources at distribution centres or district/ provincial/national programme management, or monitoring and evaluation in the personnel cost component [30, 31, 34] (see section 2.4).
Programme-Level Costs
Three studies included programme-level costs associated with ART delivery. [30, 31, 34] Across two urban sites in India, [30] programme-level costs on medical and administrative personnel other than those directly involved in ART delivery to patients were reported to be about 16% of per patient-year recurrent costs during the first year of the programme, falling to about 7% in the second year. Another study in India [31] included a project coordinator working across different health facilities under personnel cost. In urban Nigeria, [34] reported above-facility expenses included transport of drugs from federal central facilities to the ARV centres.
Paediatric Antiretroviral Treatment
We identified three studies reporting costs of ART for patients aged <15 years (for one of them, [22] unbundling paediatric from adult ART costs was not possible). In Brazil (UMIC), costs of ART in a university hospital were $US2039 per year for outpatient children; [24] weighed across all children (14% of whom were inpatient), the average yearly cost was $US2826. In Ethiopia [23] (LIC), a total cost per child-year of $US961 was found for new patients (within the first 6 months of treatment) and $US933 for established patients, with ARVs accounting for $US607 (>60% of total cost), and laboratory tests $US191 (20%) in new or $US94 (10%) in established patients.
Prevention of Mother-to-Child Transmission
Three eligible PMTCT costing studies were analysed. The cost per mother-neonate pair receiving nevirapine around child delivery was $US251.1 in India, [48] $US208.8 in South Africa [49] (both middle-income countries), but only $US6.4 in Rwanda, [50] an LIC (table III) . The large difference in costs suggests that these studies included different packages of PMTCT services and/ or different cost components (see Discussion section).
The South African study [49] presented a thorough costing in already existing facilities, focusing on the added financial costs utilized specifically by the PMTCT programme. Across four facilities, the average unit cost per HIV-infected motherneonate pair receiving prophylactic nevirapine services was $US208.8. This cost included nevirapine to mothers at delivery, as well as provision of nevirapine suspension to the infant and formula milk for the duration of the hospital stay. Additional costs estimated in the study were $US42.4 for the pre-test counselling and $US32.5 for testing costs. The study reported a substantially higher cost for post-discharge follow-up care, at $US327.2 per HIV-infected mother/infant pair covering cotrimoxazole and provision of infant formula after birth for the duration of the hospital stay (table III) . The unit costs varied according to the denominator unit used (pregnant women screened, or HIV-infected women and neonate pair receiving ARV prophylaxis) as well as between the four locations according to their economic and epidemiological differences, e.g. a high HIV prevalence and resource-poor setting (Frankfort, Free State) compared with a low HIV prevalence and better resourced setting (Paarl, Western Cape).
In Andhra Pradesh, India, [48] across 16 PMTCT centres, 1212 HIV-infected pregnant women received PMTCT, of 125 073 counselled and tested pregnant women. The average economic cost per HIV-infected woman receiving nevirapine around child delivery was $US251. Average unit cost, expressed per pregnant woman counselled and tested, irrespective of HIV status, was $US2.40. Given the low price of nevirapine, personnel was the major cost component, at $US119 or 47% of overall cost per HIV-infected woman, followed by $US37 (15%) on overheads.
In Rwanda, [50] the PMTCT unit cost per specific package was much lower, at $US6.42. The marked contrast with India and South Africa is in part explained by Rwanda's much lower percapita income level and health worker salaries. Equally important, this unit cost was achieved in a large-scale programme in a high HIV-prevalence setting, with the six health centres covering a catchment population of 148 151 individuals, with a high PMTCT uptake rate of 71.6%, which likely achieved significant economies of scale. However, the study does not specify number of pregnant women screened for PMTCT, the number of HIV-infected women or the number of motherinfant pairs given nevirapine.
Sensitivity Analyses
A first sensitivity analysis assessed the effect of aggregating unit cost within country-income groups by weighing all data points and sites across studies and countries equally, instead of the base-case model (presented above), which weighed all countries equally, irrespective of their number of data points. In this variant model, median unit costs for ART were nearly unchanged for LIC and UMIC: in LIC, the median was $US797 (vs $US792 in the base-case model) and 1397 in UMIC (vs $US1454 in the base-case model; table II). However, for LMIC, this alternative aggregation method resulted in a 3-fold reduced median cost estimate per patient-year: $US298 compared with $US932 in the base case. This difference reflects an over-representation of study sites and data points from India among LMIC, with exceptionally low unit costs reflecting India's uniquely low ARV prices due to the country's important generic ARV industry and resulting strong pharmaceutical negotiation capacity.
A second sensitivity analysis, to further check on representativeness, expanded the data set to include a number of studies that did not include a breakdown of cost components, but had data on total ART costs. With the addition of one study from Kenya, [51] the LIC median cost per patient per year became $US773 (mean: 713, range: 211-1089), similar to the original estimate of $US792. Among LMIC, adding data points from Thailand and India [52] [53] [54] did not alter the median cost per patient per year from the default of $US932 (but the mean increased to 1314, range: 162-4212).
Third, we replaced the country-income classification according to each country's 2009 income level by a classification using each country's income level in the year of cost data collection (while in both cases applying World Bank 2009 income thresholds). This shifted five countries that had grown richer between the costing study year and 2009 (Brazil, India, Lesotho, Nigeria and South Africa) into a lower income category. This country regrouping reduced the median ART per-patient cost among LIC (from $US792 to $US646), increased the estimate for LMIC (from $US932 to $US1454) and decreased the estimate for UMIC (from $US1454 to $US1241).
Discussion
Empirical data on ART delivery unit costs in low-and middle-income countries has increased significantly in recent years, as access to ART has expanded. The current review identifies several more good-quality costing studies of both outpatient and home-based ART than earlier reviews, [12, 13, 15] and provides separate cost estimates for the components ARVs, personnel and laboratory costs.
The results have several implications for programme planning and budgeting, and for seeking efficiency improvement. For ART, the key cost drivers within health facilities are ARV procurement, laboratory tests and personnel. ARV prices have declined substantially over the last decade, with average declines of 12-39% over 2006-9 for the first-line regimens most commonly used in low-and middle-income countries. [55] Lacking specification of regimens and drug sources in sites studied, it was not possible to adjust cost estimates for price declines. Only six of the 24 ART costing studies reported whether the programme used generic or innovator drugs (see the expanded versions of table I in the Supplemental Digital Content). Of 14 studies that specified ARV regimens, the majority used lamivudine (3TC) + nevirapine + stavudine (d4T) as the most common first-line regimen, the regimen for which recent price declines have been smallest: 9-12% per year. [55] The predominance of this regimen may explain why, over 2004-9, the average proportion of overall ART cost covered by ARV drugs was relatively stable, at 48-52% every year, rather than declining.
The observed large variations in laboratory costs between countries and sites indicate possible opportunities for efficiency gains. Variations may partly relate to patients' differing clinical stages and responses to treatment, [46] with laboratory costs being higher during the first 6 months after ART initiation. [23] Furthermore, laboratory costs tend to be lower in established programmes or in hospitals, for example, $US15.7 or 6% of overall cost in Ethiopia in 2004-5, [26] compared with programmes or clinics that are starting up and therefore investing more in laboratory equipment. [27] Available data (table I) were limited in the specification of laboratory tests performed, testspecific costs and precise laboratory testing practices and frequencies. We could therefore not analyse whether sites with routine, systematic CD4 and viral load monitoring were more expensive than sites with selective viral load monitoring, sites with only (or less frequent) CD4 testing, or sites with just clinical monitoring, and cannot estimate the possible savings from shifting testing patterns. In the DART (Development of AntiRetroviral Therapy in Africa) trial of clinically driven versus laboratory-guided ART in Uganda and Zimbabwe, haematology and biochemistry added little benefit. Twelve-weekly CD4 monitoring improved clinical outcomes from the 2nd year from treatment initiation onwards. However, the cost of CD4 testing would have to drop to $US3.8 (from current $US175) in order to make this monitoring practice cost effective. [56] [57] [58] Another approach to improving the efficiency of ART programmes may be personnel task shifting. [59] [60] [61] In a non-Government Organization-led programme in rural Uganda, costs to the provider were similar for clinic-based and homebased ART ($US834 and $US789 per patientyear, respectively), at comparable patient retention and clinical outcomes. [29] The study suggests an opportunity to increase ART access in settings with restrained health system capacity. The markedly higher cost of inpatient versus outpatient ART (two studies in South Africa [43, 44] [table I]) further demonstrates the financial importance of preventing hospitalizations.
Limitations
This review reflects the state of evidence in the first decade of global ART scale-up. Given the small number of studies and settings, the available data can hardly claim global representativeness. Despite the recent increase in good-quality studies (as defined in our inclusion criteria), costing information from South Asia (2 studies), Latin America and the Caribbean (5) and East Asia and the Pacific (1) remains extremely limited. Furthermore, in sub-Saharan Africa, 8 of the 16 studies were conducted in South Africa, which, with its relatively high income level, is the country least representative of the region. The lack of regional representativeness is one reason that our first sensitivity analysis found higher median ART costs in LIC than in LMIC, a result that seems contrary to intuition and to observed patterns in ARV prices. [55] Despite the inclusion of studies from the grey literature (of which seven were eligible [19, 22, 23, 27, 33, 34, 38] ), we cannot exclude the possibility of publication bias in available costing studies. Several recent, well executed ART and PMTCT cost studies that are recognized for influencing donor funding policies have not been published in books, peer-reviewed journals or made otherwise publically available, so were unfortunately not included in our metaanalyses.
Innovative monitoring and evaluation strategies are needed to address the gaps in good-quality evidence, especially concerning above-facility and programme-level costs. We intended to analyse all relevant cost components, including programme-level (above facility-level) activities and expenses, including managerial overheads, administration, monitoring and evaluation and training borne at district, province and national levels. However, only three ART studies [30, 31, 34] provided such programmatic costs, without sufficient description of the relevant activities or cost items to analyse the determinants of these potentially significant contributions to overall delivery cost.
Quality and completeness of available costing studies varied. Many did not explicitly report all cost components, missing information on such important cost determinants as ARV drugs, regimens, or type and frequency of laboratory testing used. Most studies also lacked details about variation in costs between different types of facilities and patient populations studied (in terms of, for example, age and CD4 cell count at treatment initiation). [23] Basic information on cost components was lacking in many studies; often either capital costs (such as those related to setting up laboratory equipment) or selected recurrent costs (such as utilities) were omitted. In particular, definitions of overhead costs varied, with some studies not even including any overheads. Only three studies [33, 34, 36] mentioned explicitly that their data collection instruments had been validated or piloted before application. The best studies reviewed used a micro-costing approach, where expenditures on each component of providing ART or PMTCT delivery were separately listed and valued. Even when an 'ingredients approach' was utilized, most studies in the last decade did not provide the type of ART used (not even generic vs patent, or first-vs second-line). In many studies, sample sizes appear to have been driven by clinical outcomes, rather than by costingrelated statistical considerations. Sample sizes varied between 209 (median for LIC, range 122-218) and 430 (median for UMIC, range 22-2835) patients, which may be considered appropriate for an overall estimate from one single locality. However, convenience sampling limits the precision and power to evaluate costs for relevant strata of sites, patient age groups, treatment regimens and modality and phases of treatment.
Heterogeneity in unit denominators, notably the calculation of patient-years, further complicates comparisons among studies. For illustration, a study in India [30] reported 1094 clients who 'ever started ART' (as average across sites), 939 clients 'at the end of study' and 503 clients who had been 'on therapy for the entire study period'. These authors selected the corresponding 9460 client-months of ART as an appropriate denominator unit; however, the large differences between patients starting and patients retained illustrates the critical influence that varying denominator definitions will have on unit cost estimates, especially in programmes with low patient retention and/or rapid scale-up, with many new patients initiating ART.
Future Work
The limitations in availability and comparability of existing cost data described above highlight an urgent need for development and dissemination of standardized cost-measurement methodologies and for capacity building. Awaiting such guidance and improved data quality and standardization, any cost comparisons between sites and studies should be carried out with extreme caution and attention to methodological differences; interpretations on relative efficiency will typically be limited to within-study determinants. Future strategic use of cost data for improving the efficiency of ART delivery will, in particular, benefit from more careful costing and reporting of ARV drug sources and regimens, laboratory costs by type and frequency of tests, and staff costs by type of personnel, including those above the health-facility level.
Future assessments should link costs to health outcomes, including cost differentials associated with clinical response, [46] drug toxicity and resistance. [44] This is ever more important in view of the WHO revised 2010 guidelines for adult ART in resource-limited settings, which recommended an expanded access to ART, starting at CD4 cell count <350/uL instead of the former 200/uL. In addition, a gradual phasing-out is now recommended of stavudine (d4T) in first-line regimens, to be replaced by less toxic but more costly efavirenz and/or tenofovir-based first-line regimens. [62] As countries gradually adopt and implement the new treatment guidelines over coming years, it is imperative that costing studies document the mix of patients evaluated in terms of CD4 cell counts at treatment initiation and regimens used, to facilitate interpretation of cost findings and cost determinants.
To improve the knowledge base on efficient ART and PMTCT delivery, collaboration between countries could be very important. First, to increase costing capacity and resources, and second, to exchange experiences in increasing service efficiency. Multi-country exercises should help to improve and standardize costing methodologies and tools for comprehensive data collection. Economies of scale, as apparent in some settings, [30] are worth investigating to establish more clearly if these are achieved merely by allocating fixed costs over a larger number of patients, or by improved technical efficiency (i.e. transformation of inputs to outputs) associated with programme maturation and learning.
Whenever possible (conditional on the availability of data on patient wages and other opportunity costs), both financial and economic costs should be collected. Financial costs are relevant for budgeting, while economic costs (including opportunity costs, productivity losses, transport and out-of-pocket expenditure by patients) will determine cost effectiveness and prioritization of resource allocations. For example, if an ART service package includes in-kind contributions such as food subsidies or other resources donated from external funding sources, these will influence future planning and sustainability. Ignoring such external assistance would distort the picture of overall costs and incentive structures in which an ART programme operates.
Conclusions
There is a paucity of information about unit costs for delivery of ART and PMTCT in different HIV/AIDS programmes, particularly in LIC. Future evaluations of programme-level ART and PMTCT unit costs will benefit from international guidance on standardized expenditure definitions and categories, standardized formats for specifying ARV regimen mixes, laboratory testing practices (including type of tests and frequency) and human resource disaggregation (facility level vs above-facility and programme level); as well as standardized service unit denominators (possibly including a component of service quality or patient retention). The large differences in ART unit costs observed in settings with similar epidemiological and economic characteristics deserve additional assessments focusing on cost determinants and opportunities for efficiency gain in programme implementation and scale-up. To scale-up ART and PMTCT to global universal access, innovative options are needed to contain costs while maintaining or improving quality and health gain.
